Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
about
Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia.H+/K+-ATPase inhibitors: a patent review.Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.The chiral bioconversion and preclinical pharmacokinetic analysis of (R)-(+)-rabeprazole in beagle dogs by HPLC and HPLC-MS/MS.Enantiomeric separation of proton pump inhibitors on new generation chiral columns using LC and supercritical fluid chromatography.The gastric H,K-ATPase blocker lansoprazole is an inhibitor of chloride channelsLansoprazole-sulfide, pharmacokinetics of this promising anti-tuberculous agent.Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects.Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer.Formulation Development, Process Optimization, and In Vitro Characterization of Spray-Dried Lansoprazole Enteric Microparticles.The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects.Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis.An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).Determination of S-(-)-lansoprazole in dexlansoprazole preparation by capillary zone electrophoresis.DETERMINATION OF LANSOPRAZOLE IN HUMAN SERUM BY SQUARE WAVE ADSORPTIVE STRIPPING VOLTAMMETRY
P2860
Q33771052-62BE2551-697B-408B-864C-B2D79A8C364EQ34315036-0E2160DA-E442-475E-AD0C-F207659550F4Q34378195-714DC627-7667-47E8-80B3-FE1BBA9438EAQ34736757-813E9FC6-9063-42E9-B9BF-748767C14979Q34822438-59F2B3D1-28FF-4902-BAAB-95691FA020A6Q35041864-B51270F9-29EC-410B-ABFF-923DE39240A1Q36407881-CFB7F586-9FAB-4ABE-A9D6-47E42F841EC6Q37667492-6F125880-66FD-4853-B588-04581249989BQ38514724-6C8298FC-B426-4AEE-8FB4-0C096311807AQ39477631-925BDB62-4F68-430E-9C02-33A2E9EB66B5Q42275708-29EC08B0-C19E-4B9D-93DE-54F20FA1F707Q42670209-15FF9427-4946-4775-BD22-A57493EB7790Q43734570-2F9CA047-FA5F-46BD-8312-EE0CE4759EE6Q47695925-D4046FBF-43F2-4FD8-8BD8-84B27D5FD501Q48308606-FFBC432E-EAE2-434C-9DF5-271E2A4FACD2Q58276140-55ADCB1A-75C1-45AD-A8DC-50994B4FD492
P2860
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
description
1992 nî lūn-bûn
@nan
1992 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Lansoprazole. A review of its ...... acy in acid-related disorders.
@ast
Lansoprazole. A review of its ...... acy in acid-related disorders.
@en
type
label
Lansoprazole. A review of its ...... acy in acid-related disorders.
@ast
Lansoprazole. A review of its ...... acy in acid-related disorders.
@en
prefLabel
Lansoprazole. A review of its ...... acy in acid-related disorders.
@ast
Lansoprazole. A review of its ...... acy in acid-related disorders.
@en
P2093
P1433
P1476
Lansoprazole. A review of its ...... acy in acid-related disorders.
@en
P2093
Barradell LB
McTavish D
P304
P356
10.2165/00003495-199244020-00007
P577
1992-08-01T00:00:00Z
P6179
1030375002